From June 16 to 18, 2026, the 24th CPHI & PMEC China grandly opened at Shanghai New International Expo Centre, widely recognized as Asia’s most influential one-stop sourcing platform covering the full pharmaceutical industrial chain. Drawing more than 3,700 exhibitors and over 110,000 professional buyers from 180+ countries and regions, this landmark expo connects API manufacturers, excipient suppliers, biotech labs, formulation enterprises and global pharmaceutical distributors under one roof. As a long-standing specialist in innovative cellulose-based biotech materials, Shanghai Runkey Biotech Co., Ltd returned to the exhibition floor with full-spectrum pharmaceutical-grade cellulose solutions and newly launched modified cellulose derivatives, showcasing the strength of China’s domestic functional excipient manufacturing to worldwide industry partners.

Shanghai Runkey Biotech has built solid credibility in global pharmaceutical auxiliary material markets over years of dedicated R&D and customer-centric service. Focused exclusively on cellulose derivative innovation, Runkey Biotech designs tailored biocompatible materials that serve oral solid preparations, sustained-release drug delivery systems, film coating, topical pharmaceuticals and nutritional supplement formulations. Unlike generic raw material suppliers, our team focuses on holistic solutions rather than isolated bulk chemicals, a core competitive edge highlighted repeatedly during this year’s three-day expo. Our technical specialists delivered one-on-one customized consultations throughout the show.

The expo served as an ideal bridge for face-to-face communication with global partners. Multiple clients placed trial sample orders on-site, and five enterprises signed preliminary framework cooperation agreements covering quarterly bulk supply.

Most overseas buyers shared identical core demands: stable long-term supply chains, flexible minimum order quantities and professional technical after-sales support. Runkey Biotech’s integrated service system distinguished us from competing exhibitors and strengthened client trust.

Widespread conversations at CPHI Shanghai 2026 revealed two defining trends reshaping the global excipient sector: accelerated localization substitution of high-end auxiliary materials and surging demand for bio-based, environmentally friendly raw materials. As Chinese pharmaceutical supply chains gain international recognition, Runkey Biotech plans to scale up investment in novel cellulose carriers for biologic and ophthalmic drug delivery systems in the next two years.

Moving forward, the company will keep leveraging CPHI as its core overseas marketing platform, expand market coverage in Latin America and the Middle East, and launch dedicated customer success programs for long-term global distributors. We aim to position our cellulose solutions as the preferred cost-performance option for mid-to-high-end pharmaceutical and healthcare production worldwide.

CPHI Shanghai 2026 concluded successfully for Shanghai Runkey Biotech Co., Ltd, marking another milestone in our global brand expansion journey. This exhibition not only enabled us to showcase upgraded cellulose technologies to the world but also deepened our understanding of evolving international pharmaceutical requirements.

For overseas buyers seeking reliable pharmaceutical cellulose excipients, customized support or free product samples, please visit our official website https://www.runkeycel.com to submit inquiry forms or send email to info@runkeybio.com for further discussion. We look forward to forging win-win, long-term partnerships with every global industry collaborator in the coming years.